UK Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
230.77+7.40 (+3.32%)
As of 02:51PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close223.37
Bid230.49 x 1100
Ask231.00 x 3200
Day's range224.40 - 230.90
52-week range117.58 - 231.53
Avg. volume997,008
Market cap27.601B
Beta (5Y monthly)0.80
PE ratio (TTM)N/A
EPS (TTM)-7.13
Earnings date27 Apr 2022 - 02 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est205.76
  • Motley Fool

    Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today

    Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. Ahead of the opening bell, Alnylam announced that its closely watched phase 3 Apollo-B study of the RNAi therapy, patisiran, in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met its primary endpoint of change in baseline in the 6-minute walk test at 12 months compared to placebo.

  • Business Wire

    Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass., August 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint o

  • Business Wire

    Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators

    CAMBRIDGE, Mass., August 02, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of Best Workplaces for Innovators.